Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
publishing date : 2021 - 10 - 18 symbols : Lly save search
Global Protein Therapeutics Market (2021 to 2026) - Industry Trends, Share, Size, Growth, Opportunity and Forecasts
Published: 2021-10-18 (Crawled : 23:00) - prnewswire.com
NVO | $122.75 -1.43% 0.0% 2.8M
|
Health Technology
|
| O: -0.08%
H: 1.66%
C: 1.26%
JNJ | News | $145.74 0.67% 0.0% 9.3M
|
Health Technology
|
| O: 0.49%
H: 2.64%
C: 1.85%
LLY | $745.95 -0.64% -0.1% 1.7M
|
Health Technology
|
| O: 0.03%
H: 1.46%
C: 1.36%
BAX | $39.65 0.33% 0.0% 2.3M
|
Health Technology
|
| O: 0.33%
H: 1.64%
C: 1.58%
ABBV | News | $164.66 0.25% -0.15% 4.5M
|
Health Technology
|
| O: 0.3%
H: 0.29%
C: -0.28%
ABT | News | $105.27 -0.6% -0.15% 7.3M
|
Health Technology
|
| O: 0.21%
H: 2.67%
C: 1.95%
BIIB | $190.55 -0.84% -0.84% 1.5M
|
Health Technology
|
| O: 0.1%
H: 0.61%
C: -0.69%
AMGN | $262.77 -0.49% -0.49% 2M
|
Health Technology
|
| O: 0.67%
H: 1.18%
C: 1.12%
growth
Lilly Declares Fourth-Quarter 2021 Dividend
Published: 2021-10-18 (Crawled : 20:00) - biospace.com/
LLY | $745.95 -0.64% -0.1% 1.7M
|
Health Technology
|
| O: 0.14%
H: 1.98%
C: 0.43%
Alkermes Announces Commercial Availability of LYBALVI® for the Treatment of Schizophrenia and Bipolar I Disorder
Published: 2021-10-18 (Crawled : 19:00) - biospace.com/
LLY | $745.95 -0.64% -0.1% 1.7M
|
Health Technology
|
| O: 0.14%
H: 1.98%
C: 0.43%
ALKS | $23.78 -0.96% -0.97% 1.8M
|
Health Technology
|
| O: 0.03%
H: 0.0%
C: -4.36%
treatment schizophrenia commercialization
Quest Diagnostics to Introduce Ki-67 IHC MIB-1 pharmDx, the First Companion Diagnostic for Eli Lilly and Company's Verzenio® (abemaciclib), a CDK4/6 Inhibitor for Certain People with HR+ HER2- High Risk Early Breast Cancer
Published: 2021-10-18 (Crawled : 18:00) - biospace.com/
DGX | $125.91 -0.84% -0.7% 870K
|
Health Services
|
| O: -0.18%
H: 1.13%
C: 1.04%
LLY | $745.95 -0.64% -0.1% 1.7M
|
Health Technology
|
| O: 0.14%
H: 1.98%
C: 0.43%
A | $132.44 -1.57% -0.36% 1.9M
|
Health Technology
|
| O: 0.23%
H: 1.17%
C: 0.75%
ema risk cancer breast cancer diagnostics her2+ diagnostic her2- her2
Innovent Announces ORIENT-31, a Phase 3 Study of Sintilimab in Patients with EGFR-Mutated Nonsquamous Non-Small Cell Lung Cancer with Prior EGFR-TKI Treatment, Has Met Primary Endpoint
Published: 2021-10-18 (Crawled : 01:00) - prnewswire.com
LLY | $745.95 -0.64% -0.1% 1.7M
|
Health Technology
|
| O: 0.14%
H: 1.98%
C: 0.43%
INCY | $52.82 0.19% 0.19% 1.8M
|
Health Technology
|
| O: -0.09%
H: 0.0%
C: -1.45%
treatment lung cancer cancer phase 3
Gainers vs Losers
| 64% | 36% |
Top 10 Gainers
AGBA | News | $1.02 155.0% 57.94% 120M
|
Finance
ZCMD | $2.86 108.76% 52.1% 2.3M
|
Commercial Services
INVO | $1.555 104.6% 51.13% 5M
|
Health Technology
ISPC | $0.437 105.16% 49.53% 37M
|
Professional, Scientific, and T...
WLGS | News | $0.92 84.0% 45.65% 1.6M
|
OST | $0.499 21.38% 45.26% 1.9M
|
XPON | News | $3.1 60.62% 37.74% 17M
|
TIRX | $0.7 44.39% 30.74% 58M
|
BNTC | News | $6.92 44.17% 30.64% 3.5M
|
Health Technology
GGE | $0.035 19.86% 29.3% 64M
|
Your saved searches
Save your searches and get alerts when important news are released.